Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company pioneering targeted protein degradation therapies for cancer and other challenging diseases. This news hub provides investors and industry professionals with timely updates on the company's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases, clinical trial progress reports, and partnership announcements in one centralized location. Our curated collection includes updates on key pipeline assets like cemsidomide and CFT1946, collaboration developments with Biogen and Merck, and financial disclosures essential for informed decision-making.
Discover comprehensive coverage of C4 Therapeutics' innovative TORPEDO® platform advancements, protein degrader research breakthroughs, and participation in major medical conferences. All content is sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page to stay informed about CCCC's progress in developing novel therapies that address drug resistance and undruggable targets through targeted protein degradation science. Check regularly for new developments in this cutting-edge area of biopharmaceutical research.
C4 Therapeutics (C4T), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, has announced an inducement grant for a new employee. The grant, approved by the independent directors on the Organization, Leadership and Compensation Committee, consists of non-qualified stock options to purchase 146,880 shares of C4T's common stock.
The grant was made on September 30, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is equal to the closing price of C4T's common stock on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder vesting in twelve equal monthly installments, subject to continued employment.
C4 Therapeutics (Nasdaq: CCCC) presented initial clinical data for CFT1946, an oral BRAF V600 mutant protein degrader, at the ESMO Congress 2024. The Phase 1 trial showed that CFT1946 is well-tolerated with no dose-limiting toxicities across five dose levels. Key findings include:
- Dose-dependent bioavailability and BRAF V600E protein degradation
- Early evidence of anti-tumor activity in patients who progressed after BRAF inhibitor therapies
- 16 out of 27 evaluable patients demonstrated tumor reduction
- Two confirmed partial responses, including a 67% decrease in a melanoma patient and a 55% decrease in a pancreatic cancer patient
The trial continues with monotherapy and combination expansion cohorts. Additional data is expected in 2025.
C4 Therapeutics (Nasdaq: CCCC) has successfully delivered a second development candidate to Biogen, earning an $8 million milestone payment. This marks the final development candidate under their strategic collaboration. The delivered candidate is a highly catalytic, brain penetrant orally bioavailable BiDAC™ degrader.
C4T's TORPEDO® platform has demonstrated its potential to design innovative degraders against various target classes. Since 2015, C4T has advanced four development candidates for its clinical pipeline and delivered two to Biogen. Under the 2018 collaboration, C4T provided expertise in targeted protein degradation, while Biogen offered scientific and drug development capabilities. Biogen is responsible for future clinical development and commercialization of the delivered candidates.
C4 Therapeutics (Nasdaq: CCCC) announced the release of an abstract containing clinical data from its ongoing Phase 1 trial of CFT1946, a novel BiDAC™ degrader, for mutant BRAF V600 solid tumors. The abstract, with a data cut-off of April 12, 2024, is available on the ESMO Congress 2024 website. An oral presentation scheduled for September 13, 2024, will provide updated data on 36 patients with a cut-off date of July 19, 2024.
The presentation will include patient demographics, safety, pharmacokinetic, pharmacodynamic, and anti-tumor activity data measured by RECIST 1.1 criteria. C4T will host a webcast for analysts and investors on September 13, 2024, at 12:00 pm ET to discuss the findings.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, has appointed Stephen Fawell, Ph.D. to its Board of Directors. Dr. Fawell brings nearly 35 years of drug discovery experience, particularly in oncology. He recently served as vice president of oncology small molecule drug discovery at AstraZeneca, where he advanced over 25 new drugs into clinical trials and supported the development of several approved medications.
Concurrently, Malcolm Salter is retiring from the Board after nearly a decade of service. The company's CEO, Andrew Hirsch, expressed excitement about leveraging Dr. Fawell's expertise in drug discovery and development, aligning with C4 Therapeutics' focus on developing degrader medicines. Dr. Fawell stated his enthusiasm for joining the board and supporting the management team in advancing their portfolio towards pivotal milestones.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, has announced its participation in two upcoming investor conferences in September 2024. The company's management will engage in fireside chats at the following events:
- Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024, at 8:45 AM ET
- 2024 Cantor Global Healthcare Conference in New York, NY on September 18, 2024, at 8:35 AM ET
Both events will feature live webcasts accessible through C4 Therapeutics' website, with archived replays available for approximately 30 days after the live events.
C4 Therapeutics (Nasdaq: CCCC) announced that the European Society for Medical Oncology (ESMO) Congress has upgraded their previously accepted preliminary Phase 1 abstract for CFT1946, a novel BiDAC™ degrader for mutant BRAF V600 solid tumors, to an oral presentation. The presentation is scheduled for September 13, 2024, at 4:00 pm to 5:30 pm CEST. Dr. Maria Vieito from Barcelona will present the preliminary results from the Phase 1 study. C4T will also host an investor webcast on the same day to discuss the CFT1946 monotherapy data from the ongoing trial. This change in presentation format suggests increased interest in C4T's research, potentially indicating promising preliminary results for their targeted protein degradation approach in oncology.
C4 Therapeutics (Nasdaq: CCCC) reported Q2 2024 financial results and business highlights. Key points include:
- Preliminary CFT1946 Phase 1 data for BRAF V600X solid tumors to be presented at ESMO Congress 2024
- Cemsidomide Phase 1 trial progressing; data expected in Q4 2024
- Cash position of $295.7 million as of June 30, 2024, providing runway into 2027
- Q2 2024 revenue: $12.0 million, up from $2.7 million in Q2 2023
- Q2 2024 net loss: $17.7 million, improved from $35.9 million in Q2 2023
- Net loss per share: $0.26, compared to $0.73 in Q2 2023
The company continues to advance its clinical programs and expects multiple data readouts in H2 2024.
C4 Therapeutics (Nasdaq: CCCC) has announced that preliminary data from the monotherapy dose escalation portion of their ongoing Phase 1/2 clinical trial of CFT1946 will be presented at the ESMO Congress 2024 in Barcelona, Spain. CFT1946 is a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors. The presentation, titled 'Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors,' will be delivered as a mini oral presentation on September 14, 2024. This presentation marks an important milestone in C4 Therapeutics' development of targeted protein degradation therapies and could provide valuable insights into the potential efficacy of CFT1946 in treating BRAF V600 mutant solid tumors.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, will participate in the UBS Targeted Protein Degradation Day, held virtually on July 15, 2024. The company's management will engage in a fireside chat from 12:00 pm ET to 12:30 pm ET. A live webcast of the event will be accessible on the Investors section of C4 Therapeutics' website, with a replay available for 30 days post-event.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
